Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
abbvie
4
×
clinical trials
life sciences
national blog main
national top stories
biotech
boston blog main
boston top stories
eli lilly
fda
new york blog main
allergan
europe blog main
merck
national
new york top stories
4d molecular therapeutics
acne
acorda therapeutics
agenus
alkermes
amgen
ampyra
apokyn
apomorphine
astrazeneca
auris health
avexis
bayer
biohaven
biomx
bladder cancer
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
broad institute of mit and harvard
buprenorphine
cancer
cancer immunotherapy
cancer vaccines
What
fda
4
×
treatment
4
×
approved
drug
disease
new
nod
acorda
adults
alkermes
allergan
antipsychotic
benefits
bio
caveats
class
commonly
companies
cope
designed
digital
effect
epidemic
episodes
fatty
favor
frenzied
friday
gain
gets
growing
help
known
late
led
liver
looms
meant
medications
medicine
Language
unset
Current search:
abbvie
×
fda
×
treatment
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
4 years ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms